The “Atopic Dermatitis Pipeline Insight, 2026” report by DelveInsight presents detailed insights into the current clinical development landscape along with potential growth opportunities within the Atopic Dermatitis market.
According to DelveInsight’s evaluation, the global Atopic Dermatitis pipeline currently includes more than 100 key pharmaceutical and biotechnology companies working on the development of over 120 therapeutic candidates for the treatment of atopic dermatitis. The analysis highlights clinical trials, therapy profiles, mechanisms of action, routes of administration, and recent development trends.
The Atopic Dermatitis Pipeline report provides a comprehensive commercial and clinical evaluation of drug candidates ranging from the preclinical stage to marketed therapies. It also includes a detailed overview of each drug, covering its mechanism of action, ongoing and completed clinical trials, regulatory approvals such as NDAs (where applicable), and development activities including technology platforms, partnerships, mergers and acquisitions, funding initiatives, regulatory designations, and other relevant product-related developments.
Download a complimentary sample PDF report to explore the therapeutic assessment of the Atopic Dermatitis pipeline: https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight
Key Highlights from the Atopic Dermatitis Pipeline Report
- Pharmaceutical and biotechnology companies worldwide are actively pursuing the development of innovative therapies for Atopic Dermatitis, with significant progress observed in recent years.
- Several companies—including Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, and Arcutis Biotherapeutics, among others—are actively developing treatment options for atopic dermatitis.
- Prominent emerging therapies under various stages of clinical development include PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, and Roflumilast, which are expected to influence the future treatment landscape of atopic dermatitis.
- In December 2025, Elanco Animal Health Incorporated (NYSE: ELAN) strengthened its position in the canine dermatology segment after receiving USDA approval for Befrena™ (tirnovetmab). This anti-IL31 monoclonal antibody injection is designed to treat canine allergic and atopic dermatitis and is administered at 6–8 week intervals, compared with the 4–8 week dosing schedule of the currently available competitor therapy, lokivetmab.
- Also in December 2025, Enveda, a clinical-stage biotechnology company focused on small-molecule medicines inspired by natural compounds, launched two concurrent Phase IIa clinical trials evaluating ENV-294, a first-in-class oral therapy for moderate-to-severe atopic dermatitis and asthma. Initiating these studies represents a significant milestone for the company. Considering that many patients still rely on injectable biologic treatments, a safe and effective oral therapy could provide a valuable alternative for individuals living with AD.
- In December 2025, Kymera Therapeutics reported encouraging preliminary results for KT-621, the first oral STAT6 degrader to enter clinical development. The therapy demonstrated reductions in disease severity and type-2 inflammatory biomarkers comparable to biologic treatments in patients with moderate-to-severe AD. In the Phase Ib BroADen trial involving 22 participants, once-daily KT-621 achieved a 63% average decrease in EASI scores within four weeks, along with rapid itch reduction and strong suppression of inflammatory markers. The therapy was also well tolerated, with no treatment-related adverse events reported.
- During December 2025, Zai Lab (ZLAB) initiated a global Phase I/Ib clinical study evaluating ZL-1503, a bispecific antibody targeting IL-13 and IL-31R for the treatment of atopic dermatitis. The trial will assess the therapy’s safety, tolerability, pharmacokinetics, and preliminary efficacy. ZL-1503 has been engineered with an extended half-life and dual-target activity, potentially enabling faster therapeutic responses and improved overall treatment outcomes.
- In September 2025, findings from the Phase III ASCEND trial (NCT05882877) demonstrated that rocatinlimab, developed by Amgen and Kyowa Kirin, provided sustained clinical improvement while maintaining a favorable long-term safety profile in adults with moderate-to-severe atopic dermatitis. Rocatinlimab targets the OX40 pathway to rebalance T-cell activity, aiming to reduce chronic inflammation and decrease treatment frequency.
- In June 2025, TRex Bio, a biotechnology company based in the United States, initiated dosing in healthy volunteers in a clinical study evaluating TRB-061 for the treatment of atopic dermatitis. TRB-061 is a TNFR2 agonist designed to activate and expand regulatory T cells within tissues, helping restore immune balance in inflammatory disorders such as eczema.
- In March 2025, Amgen and Kyowa Kirin announced that their Phase III IGNITE trial evaluating two dose levels of rocatinlimab successfully achieved its co-primary endpoints after 24 weeks. Additionally, all key secondary endpoints demonstrated statistically significant improvements compared with placebo. The randomized, double-blind trial enrolled 769 adult patients, including individuals previously treated with biologics or JAK inhibitors.
- Also in March 2025, Hudson Therapeutics, the U.S. division of Shaperon, revealed plans to initiate Phase IIb Part 2 of its clinical study evaluating NuGel, a novel inflammasome inhibitor intended for mild-to-moderate atopic dermatitis. A kickoff meeting held in the United States marked an important milestone in advancing the therapy’s global clinical development.
- In December 2024, Corvus Pharmaceuticals (NASDAQ: CRVS) released interim findings from its Phase I randomized, double-blind, placebo-controlled trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis. The results demonstrated encouraging safety and efficacy, highlighting the potential of ITK inhibition as a novel therapeutic approach for immune-mediated diseases.
- In November 2024, Enveda received FDA clearance for its Investigational New Drug (IND) application targeting atopic dermatitis and other inflammatory conditions. The company subsequently launched a Phase I clinical trial for its lead candidate ENV-294, with the first patient dosed in October.
- In August 2024, Lynk Pharmaceuticals reported positive outcomes from its Phase Ib clinical trial of LNK01004, a new topical therapy for atopic dermatitis. The randomized, placebo-controlled, multi-center study assessed the safety, tolerability, and pharmacokinetics of the drug in adults with mild-to-moderate AD.
- In March 2024, Sanofi announced promising results from a second-phase study evaluating amlitelimab, an OX40 antibody, which demonstrated sustained clinical improvement in patients with moderate-to-severe atopic dermatitis.
Atopic Dermatitis Overview
Atopic dermatitis, widely referred to as eczema, is a long-term inflammatory skin disorder characterized by itchy, red, and irritated skin rashes. The condition typically occurs in individuals with a personal or familial history of allergic disorders such as asthma, hay fever, or allergic rhinitis, and it often presents with periodic flare-ups.
Stay informed about emerging therapies, ongoing clinical trials, and market trends in atopic dermatitis through comprehensive pipeline insights and clinical trial analysis: https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight
Emerging Atopic Dermatitis Drugs in Clinical Development
Some of the prominent therapies currently being evaluated include:
- PF 07242813 – Pfizer
- KT-474 – Kymera Therapeutics
- BEN2293 – BenevolentAI
- MEDI3506 – AstraZeneca
- Q301 – Qurient
- SB011 – Sterna Biologicals
- Tradipitant – Vanda Pharmaceuticals
- Roflumilast – Arcutis Biotherapeutics
Route of Administration for Atopic Dermatitis Therapies
The report categorizes pipeline therapies based on route of administration (ROA), including:
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Types in the Atopic Dermatitis Pipeline
Atopic dermatitis therapies are also classified according to molecular type, including:
- Recombinant fusion proteins
- Small molecules
- Monoclonal antibodies
- Peptides
- Polymers
- Gene therapies
Therapeutic Assessment of the Atopic Dermatitis Pipeline
The report evaluates therapies based on:
- Product type
- Development stage
- Route of administration
- Molecular structure
Get detailed analysis of each marketed and emerging drug @ https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight
DelveInsight’s report covers approximately 120+ pipeline products across multiple stages of development, including:
- Late-stage therapies (Phase III)
- Mid-stage therapies (Phase II)
- Early-stage therapies (Phase I)
- Preclinical and discovery candidates
- Discontinued or inactive programs
Key Companies in the Atopic Dermatitis Therapeutics Market
Major companies involved in the development of therapies for atopic dermatitis include GlaxoSmithKline PLC, Nestlé SA, Pfizer Inc., Regeneron Pharmaceuticals Inc., AbbVie Inc., Allergan PLC, Bausch Health Companies Inc., Evelo Biosciences, Cara Therapeutics, Bristol-Myers Squibb, Sanofi S.A., and LEO Pharma, among others.
Atopic Dermatitis Pipeline Analysis
The pipeline report provides comprehensive insights, including:
- Detailed profiles of companies developing therapies for atopic dermatitis
- Evaluation of therapeutic candidates across early, mid, and late stages of development
- Identification of both active and inactive research programs
- Analysis of drugs based on development stage, route of administration, molecular type, target receptor, and treatment approach (monotherapy or combination therapy)
- Assessment of collaborations, licensing agreements, funding activities, and partnership deals shaping the future of the atopic dermatitis market
The analysis is compiled using data sourced from proprietary databases, company websites, clinical trial registries, conference presentations, SEC filings, investor reports, press releases, and other industry resources.
Request for free sample report at zero cost: https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight
Market Drivers
Key factors driving the growth of the atopic dermatitis pipeline market include:
- Increasing prevalence of atopic dermatitis
- Rising healthcare expenditure
- Development of innovative emerging therapies
Market Barriers
However, certain challenges continue to limit market growth, such as:
- Availability of over-the-counter treatment options
- Outdated treatment guidelines
- Poor treatment adherence and disease prognosis
Scope of the Atopic Dermatitis Pipeline Insight
- Coverage: Global
- Key companies involved include Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others.
- Key therapies include PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, and Roflumilast.
The report provides insights into current marketed therapies, emerging pipeline treatments, and market dynamics, including growth drivers and barriers. Download free sample report now: https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight
About DelveInsight
DelveInsight is a prominent business consulting and market research firm specializing in life sciences and healthcare. The company supports pharmaceutical and biotechnology organizations by delivering comprehensive market intelligence, strategic insights, and end-to-end consulting solutions designed to enhance performance, accelerate business growth, and address complex market challenges through practical and data-driven approaches.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting